The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AG-F-90842     2-[[5-methoxy-1-[4- (trifluoromethyl)phenyl...

Synonyms: ANW-64084, SPBio_002980, AC1L1FUZ, CTK8C0094, CTK8D6408, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of fluvoxamine


Psychiatry related information on fluvoxamine


High impact information on fluvoxamine


Chemical compound and disease context of fluvoxamine


Biological context of fluvoxamine


Anatomical context of fluvoxamine

  • We measured ALLO content in four cisternal-lumbar fractions of cerebrospinal fluid (CSF) before and 8-10 weeks after treatment with fluoxetine or fluvoxamine in 15 patients with unipolar major depression [23].
  • High-speed in vivo electrochemical recordings were used to assess the ability of the SSRI fluvoxamine to modulate the clearance of locally applied serotonin in the CA3 region of hippocampus in drug- or vehicle-treated rats [24].
  • CONCLUSIONS: After improvement of OCD with either fluvoxamine or behavioral therapy, hyperactivation of the frontal lobe related to a symptom-provocative state decreases, and posterior brain activity related to action-monitoring function increases [25].
  • A comparison of the effects of imipramine and fluvoxamine on the thyroid axis [26].
  • In a human liver microsome preparation, fluvoxamine showed a concentration-dependent inhibition of clozapine N-demethylation [27].

Associations of fluvoxamine with other chemical compounds


Gene context of fluvoxamine


Analytical, diagnostic and therapeutic context of fluvoxamine

  • Effective pharmacotherapy of alcoholic amnestic disorder with fluvoxamine. Preliminary findings [14].
  • METHOD: During phase I, patients participated in a double-blind study of the effects of imipramine versus fluvoxamine, with final evaluation of response 4 weeks after patients attained the target plasma level [29].
  • Brain fluvoxamine concentration in the children was lower, consistent with a lower dose/body mass drug prescription; when brain concentration was adjusted for dose/mass, age effects were no longer significant [15].
  • RESULTS: Compared with placebo, fluvoxamine was associated with a significantly greater rate of reduction in the frequency of binges, rate of reduction in CGI severity scores, rate of increase in CGI improvement scores, level of response for patients who completed the 9-week study, and rate of reduction in body mass index [2].
  • METHODS: The serum concentration of fluvoxamine was determined by high-performance liquid chromatography for 48 hours after oral administration of a single dose of 50 mg fluvoxamine to 12 smokers (> or = 10 cigarettes per day) and 12 nonsmokers [35].


  1. Toxic epidermal necrolysis after fluvoxamine. Wolkenstein, P., Revuz, J., Diehl, J.L., Langeron, O., Roupie, E., Machet, L. Lancet (1993) [Pubmed]
  2. Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial. Hudson, J.I., McElroy, S.L., Raymond, N.C., Crow, S., Keck, P.E., Carter, W.P., Mitchell, J.E., Strakowski, S.M., Pope, H.G., Coleman, B.S., Jonas, J.M. The American journal of psychiatry. (1998) [Pubmed]
  3. Neuroleptic malignant syndrome induced by quetiapine and fluvoxamine. Matsumoto, R., Kitabayashi, Y., Nakatomi, Y., Tsuchida, H., Fukui, K. The American journal of psychiatry. (2005) [Pubmed]
  4. Treatment of irritable bowel syndrome with fluvoxamine. Emmanuel, N.P., Lydiard, R.B., Crawford, M. The American journal of psychiatry. (1997) [Pubmed]
  5. Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone. de Beurs, E., van Balkom, A.J., Lange, A., Koele, P., van Dyck, R. The American journal of psychiatry. (1995) [Pubmed]
  6. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. Isaacs, E. N. Engl. J. Med. (2001) [Pubmed]
  7. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Goodman, W.K., Price, L.H., Rasmussen, S.A., Delgado, P.L., Heninger, G.R., Charney, D.S. Arch. Gen. Psychiatry (1989) [Pubmed]
  8. A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Black, D.W., Wesner, R., Bowers, W., Gabel, J. Arch. Gen. Psychiatry (1993) [Pubmed]
  9. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Goodman, W.K., Price, L.H., Delgado, P.L., Palumbo, J., Krystal, J.H., Nagy, L.M., Rasmussen, S.A., Heninger, G.R., Charney, D.S. Arch. Gen. Psychiatry (1990) [Pubmed]
  10. Fluvoxamine and epilepsy. Vincenti, G.E. Lancet (1990) [Pubmed]
  11. High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Suhara, T., Takano, A., Sudo, Y., Ichimiya, T., Inoue, M., Yasuno, F., Ikoma, Y., Okubo, Y. Arch. Gen. Psychiatry (2003) [Pubmed]
  12. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. McDougle, C.J., Naylor, S.T., Cohen, D.J., Volkmar, F.R., Heninger, G.R., Price, L.H. Arch. Gen. Psychiatry (1996) [Pubmed]
  13. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. McDougle, C.J., Goodman, W.K., Leckman, J.F., Lee, N.C., Heninger, G.R., Price, L.H. Arch. Gen. Psychiatry (1994) [Pubmed]
  14. Effective pharmacotherapy of alcoholic amnestic disorder with fluvoxamine. Preliminary findings. Martin, P.R., Adinoff, B., Eckardt, M.J., Stapleton, J.M., Bone, G.A., Rubinow, D.R., Lane, E.A., Linnoila, M. Arch. Gen. Psychiatry (1989) [Pubmed]
  15. Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders. Strauss, W.L., Unis, A.S., Cowan, C., Dawson, G., Dager, S.R. The American journal of psychiatry. (2002) [Pubmed]
  16. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. McDougle, C.J., Goodman, W.K., Leckman, J.F., Holzer, J.C., Barr, L.C., McCance-Katz, E., Heninger, G.R., Price, L.H. The American journal of psychiatry. (1993) [Pubmed]
  17. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. McDougle, C.J., Goodman, W.K., Price, L.H., Delgado, P.L., Krystal, J.H., Charney, D.S., Heninger, G.R. The American journal of psychiatry. (1990) [Pubmed]
  18. 19F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder. Strauss, W.L., Layton, M.E., Hayes, C.E., Dager, S.R. The American journal of psychiatry. (1997) [Pubmed]
  19. Newer antidepressants and the cytochrome P450 system. Nemeroff, C.B., DeVane, C.L., Pollock, B.G. The American journal of psychiatry. (1996) [Pubmed]
  20. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Smeraldi, E., Zanardi, R., Benedetti, F., Di Bella, D., Perez, J., Catalano, M. Mol. Psychiatry (1998) [Pubmed]
  21. Brain elimination half-life of fluvoxamine measured by 19F magnetic resonance spectroscopy. Strauss, W.L., Layton, M.E., Dager, S.R. The American journal of psychiatry. (1998) [Pubmed]
  22. Pharmacokinetics of the newer antidepressants: clinical relevance. DeVane, C.L. Am. J. Med. (1994) [Pubmed]
  23. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Uzunova, V., Sheline, Y., Davis, J.M., Rasmusson, A., Uzunov, D.P., Costa, E., Guidotti, A. Proc. Natl. Acad. Sci. U.S.A. (1998) [Pubmed]
  24. Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. Benmansour, S., Cecchi, M., Morilak, D.A., Gerhardt, G.A., Javors, M.A., Gould, G.G., Frazer, A. J. Neurosci. (1999) [Pubmed]
  25. Brain activation of patients with obsessive-compulsive disorder during neuropsychological and symptom provocation tasks before and after symptom improvement: a functional magnetic resonance imaging study. Nakao, T., Nakagawa, A., Yoshiura, T., Nakatani, E., Nabeyama, M., Yoshizato, C., Kudoh, A., Tada, K., Yoshioka, K., Kawamoto, M., Togao, O., Kanba, S. Biol. Psychiatry (2005) [Pubmed]
  26. A comparison of the effects of imipramine and fluvoxamine on the thyroid axis. Brady, K.T., Lydiard, R.B., Kellner, C.H., Joffe, R., Laird, L.K., Morton, W.A., Steele, T.E. Biol. Psychiatry (1994) [Pubmed]
  27. Fluvoxamine-Clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism. Olesen, O.V., Linnet, K. Journal of clinical psychopharmacology. (2000) [Pubmed]
  28. Influence of a functional polymorphism within the promoter of the serotonin transporter gene on the effects of total sleep deprivation in bipolar depression. Benedetti, F., Serretti, A., Colombo, C., Campori, E., Barbini, B., di Bella, D., Smeraldi, E. The American journal of psychiatry. (1999) [Pubmed]
  29. Comparison of two-phase treatment with imipramine or fluvoxamine, both followed by lithium addition, in inpatients with major depressive disorder. Birkenhäger, T.K., van den Broek, W.W., Mulder, P.G., Bruijn, J.A., Moleman, P. The American journal of psychiatry. (2004) [Pubmed]
  30. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Kashuba, A.D., Nafziger, A.N., Kearns, G.L., Leeder, J.S., Gotschall, R., Rocci, M.L., Kulawy, R.W., Beck, D.J., Bertino, J.S. Clin. Pharmacol. Ther. (1998) [Pubmed]
  31. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Fogelman, S.M., Schmider, J., Venkatakrishnan, K., von Moltke, L.L., Harmatz, J.S., Shader, R.I., Greenblatt, D.J. Neuropsychopharmacology (1999) [Pubmed]
  32. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Lane, R.M. International clinical psychopharmacology. (1996) [Pubmed]
  33. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation. Schmider, J., Greenblatt, D.J., von Moltke, L.L., Karsov, D., Shader, R.I. British journal of clinical pharmacology. (1997) [Pubmed]
  34. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Rasmussen, B.B., Maënpää, J., Pelkonen, O., Loft, S., Poulsen, H.E., Lykkesfeldt, J., Brøsen, K. British journal of clinical pharmacology. (1995) [Pubmed]
  35. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Spigset, O., Carleborg, L., Hedenmalm, K., Dahlqvist, R. Clin. Pharmacol. Ther. (1995) [Pubmed]
WikiGenes - Universities